Minnesota Medical Cannabis Product Requirements for 2027

For a Minnesota medical cannabis patient, another dispensary opening becomes more useful when the store can supply the product they use. A menu full of flower does not answer a question about a particular CBD formulation or an oral liquid. That practical distinction is the point of the Office of Cannabis Management's October 12, 2026 high medical need product guidance.

The list identifies four formulations and the forms that medically endorsed retail locations must carry. The associated manufacturing, retail and enforcement provisions in Laws 2026, chapter 123, sections 97, 98 and 102 each take effect January 1, 2027. Publishing the list in October does not move those effective dates forward.

If you are arranging a refill this fall, check your actual shop's inventory and consultation process. The new list is a useful planning tool, but it is not a promise that your usual brand is on every shelf today. Our Minnesota medical card guide covers enrollment separately; this article focuses on product access during the transition.

What the October list changes

OCM's memo, numbered GM 2026 08, describes a category based inventory standard. It identifies products the office considers important to patients and unlikely to be adequately supplied by the broader market without a specific obligation. It does not list a preferred brand, assign a particular product to a particular patient, or turn the largest THC number on a package into a treatment recommendation.

That makes the list different from a store menu. A menu tells you what a business says it sells. The OCM list tells you which combinations of formulation and form the office expects medically endorsed retail locations to carry under the new requirements. You need both pieces of information when checking whether a store can serve your needs.

The 2026 omnibus bill guide explains the wider licensing transition. Product access is one part of that transition, alongside the separate rules for consultations and service to enrolled patients. An adult use retail license by itself should not be treated as proof of a medical retail endorsement.

Read the formulation and form together

A formulation describes the cannabinoid composition. A form describes how the product is administered. Changing either one can change which category you are looking at. A bottle labeled with a familiar ratio is not automatically the same thing as a pill with that ratio.

Here is the retail stocking matrix in OCM's October 12 memo:

In the table, the enteral liquid category means water soluble cannabinoid multiparticulate or oral solution or suspension. The oromucosal category means an orally dissolvable product or tincture. These are summaries of the categories in the official memo, not an instruction to substitute one product for another without consultation.

The distinction in the last row matters. High THC products require one of the listed forms. Balanced products require each of the three categories. CBD only and high CBD products require each of their two listed categories. Saying every formulation must be sold in every form would overstate the memo.

There is also no useful fixed number of stock keeping units to infer from this table. A balanced product with at least 20 mg THC per serving could meet the high THC formulation definition as well. The memo describes categories; it does not establish a simple arithmetic count of unique brands or packages.

Ratios are specifications, not suggested doses

The high CBD category starts at one part THC to fifteen parts CBD. The balanced category uses equal amounts of THC and CBD. The high THC category requires at least 20 mg THC per serving and permits CBD up to the THC amount. CBD only has its own category.

Those numbers are regulatory product definitions. They are not instructions about how much you should take, a claim that a higher dose is better, or a prediction of how a product will affect an individual. Bring the actual label and your questions to the appropriate medical professional or consultation.

It helps to write the ratio in the same order as the source. In this memo that order is THC:CBD. Reversing it changes the meaning: 1:15 THC:CBD has substantially more CBD than THC, while 15:1 THC:CBD describes something quite different. Ask the shop to identify both amounts rather than relying on a nickname such as balanced or strong.

For broader reading on product terminology, the Hub's cannabinoid explainer covers the vocabulary. It does not replace a patient consultation or make a specific product medically appropriate for you.

Manufacturing and retail endorsements do different jobs

Section 97 creates obligations for businesses with a medical cannabis manufacturer endorsement, including manufacturing the office's identified high medical need products. Section 98 addresses medical cannabis retail endorsements, including carrying the identified products and providing the specified patient service and consultation arrangements.

These are separate roles. A manufacturer endorsement is not a retail endorsement. A business being licensed to sell adult use cannabis does not, by that fact alone, establish that it can sell the listed medical products to you. When asking about a location, ask about the retail endorsement at that location rather than assuming a brand name settles the question.

The October memo also says none of the product types on its list are currently approved adult use product types. It describes them as products manufactured and sold through medical endorsements. Do not read a product being listed as permission for any adult customer to buy it off an ordinary recreational menu.

The dispensary directory can help you identify nearby businesses. Confirm current medical services, enrollment checks and product availability directly with the location before traveling. A directory listing is a starting point for that conversation, not a certification of today's inventory.

January 1 is the date to keep straight

The October 12 publication provides the list before the new requirements take effect. The law's effective date clauses are explicit: sections 97, 98 and 102 begin January 1, 2027. That timing matters for both patient expectations and reporting about whether a business is following the new standard.

Some provisions of the omnibus law use August 1, 2026. Those dates should not be carried over to these medical endorsement provisions. Our August law changes guide separates the dates so a headline about the broader law does not make every change sound immediate.

A useful way to frame a conversation this fall is to ask how a retailer is preparing for January, while asking separately what it can provide now. You can then plan around a concrete answer about today's stock rather than a general statement that a new rule is coming.

What the 24 hour provision actually says

Section 102 gives OCM enforcement authority and permits the office to suspend or revoke a medical endorsement when it determines a business is not actively participating in the medical market. One specified basis is failure to make identified high medical need products available at each retail location within 24 hours of a patient request. That section also begins January 1, 2027.

This is an enforcement provision, not a guarantee that a product will appear instantly, that a particular brand must be supplied, or that a patient's preferred package size is protected. Nor does it tell a patient to change a regimen while waiting. A careful account should preserve both the requirement and its limits.

If you encounter an availability problem after the provision takes effect, keep the location, date, requested product category and the response you received. Ask the business what it can provide and when. If the issue remains unresolved, the official OCM website provides a complaint channel. A clear record of the request is more useful than an assumption based on an empty online menu.

Questions to ask before your next trip

Start with the product information you already have: name, formulation, form and the label's amounts per serving. A photograph of the label can make the conversation more precise. Ask whether that exact product is available, then ask about the relevant OCM category if it is not.

Ask the retailer these questions:

• Does this location have a medical cannabis retail endorsement?
• What enrollment documentation and identification should I bring?
• Is the product in stock at this location, and when was that checked?
• Which formulation and administration category does it meet?
• How do I arrange any required consultation?
• If it is unavailable, how can I document a request and receive an update?

Confirm the answer for the location you plan to visit. A chain's general website or a menu from another city may not reflect local stock. Ask about accessibility needs directly, including whether the product form you use is available; do not assume a tablet and liquid are interchangeable.

For enrollment procedures, use OCM's patient frequently asked questions and the Hub's medical enrollment walkthrough. This product list does not eliminate the registry process or establish a new certification fee.

Frequently asked questions

Does the October 12 HMN memo make the January stocking rules immediate?

No. The memo publishes the product categories, while the associated manufacturing, retail endorsement and enforcement provisions explicitly take effect January 1, 2027. Ask a store about current stock separately from its preparations for those obligations.

Must high THC products be available in all three listed administration categories?

No. The October memo requires one of the three listed forms for that formulation. Balanced products have a different requirement: pills, the enteral liquid category and the oromucosal category must each be carried.

Does an HMN formulation protect my usual brand or package size?

The memo identifies formulations and administration categories rather than individual brands or package sizes. Confirm the exact product with the retailer, and use a consultation to discuss any proposed alternative instead of treating a shared ratio as proof of equivalence.

Why should patients avoid turning the matrix into a fixed SKU count?

Some formulation definitions can overlap. A sufficiently potent balanced product can also fit the high THC definition. The office's category requirements therefore do not translate into a reliable count of unique packages or brands by simply adding the table's cells.

Does the 24 hour patient request rule promise a refill on demand today?

No. Section 102 begins January 1, 2027 and describes OCM's enforcement authority, including failure to make listed products available within 24 hours of a patient request. It is not an immediate availability guarantee or a promise of a specific brand.

Sources and review date

Reviewed October 14, 2026 against OCM guidance memo GM 2026 08, published October 12, Laws 2026, chapter 123, sections 97, 98 and 102, and OCM patient FAQs. Product definitions describe the office's access requirements and are not individualized medical advice.